Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus capecitabine versus trastuzumab plus capecitabine after local therapy for HER2-positive metastatic breast cancer with brain metastases
ISRCTN58771616Phase 2Terminated
- Sponsor
- Leeds Teaching Hospitals NHS Trust
- Start
- Mar 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of lapatinib, capecitabine and trastuzumab in breast cancer, sponsored by Leeds Teaching Hospitals NHS Trust. Primary endpoint: Time to progression of central nervous system metastases. Started Mar 2011; status: terminated.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ISRCTN58771616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN58771616.